(Q58802176)

English

Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin

No description defined

In more languages

Statements

scholarly article

0 references

Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin (English)

0 references

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

based on heuristic

inferred from title

Hiroyuki Yoshikawa

12

object named as

Hiroyuki Yoshikawa

0 references

13

object named as

Toyomi Satoh

0 references

Takeo Minaguchi

2

object named as

Takeo Minaguchi

0 references

11

object named as

Hiroyuki Ochi

0 references

10

object named as

Sari Nakao

0 references

9

object named as

Manabu Sakurai

0 references

7

object named as

Ayumi Shikama

0 references

Nobutaka Tasaka

8

object named as

Nobutaka Tasaka

0 references

3

object named as

Azusa Akiyama

0 references

Bouchra Lachkar

1

object named as

Bouchra Lachkar

0 references

author name string

Shuling Liu

4

0 references

Shuang Zhang

5

0 references

Chenyang Xu

6

0 references

language of work or name

0 references

publication date

August 2018

0 references

0 references

97

0 references

31

0 references

e11392

0 references

Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Cisplatin: mode of cytotoxic action and molecular basis of resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6081058

30 November 2018

PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30075505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MD.0000000000011392

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58802176&oldid=2043504097"